aTENSION.life GmbH

aTENSION. life GmbH specializes in hypertension management, offering innovative diagnostic solutions to enhance patient care and improve clinical workflows. Their flagship product utilizes advanced testing technology to deliver precise measurements for effective treatment strategies. aTENSION.

life GmbH, founded in 2024 in Vienna, Austria, focuses on advancing hypertension care through novel diagnostic platforms. The company has completed 1 deal, with the most recent funding round occurring on April 10, 2025. During this round, aTENSION. life raised USD 3.

000 mn in Seed funding, co-led by new investors Wlanholding and eQventure, with participation from VP Venture Partners. The founder’s history and details about prior ventures are not publicly available. aTENSION. life is focused on advancing hypertension care through its core product, the ALDO+ testing platform, which utilizes mass spectrometry to provide precise diagnostics for hypertension management.

This innovative testing solution allows for the direct measurement of key hormones such as Angiotensin I, Angiotensin II, and Aldosterone from a single blood sample, offering critical insights into the Renin-Angiotensin-Aldosterone System (RAAS). The ALDO+ platform is especially significant for identifying primary aldosteronism, a common form of secondary hypertension that often goes undiagnosed due to inadequate screening rates. The company's products target healthcare professionals, including clinicians and laboratories, aiming to improve diagnosis and treatment plans for hypertensive patients. aTENSION's services are expanding into various geographical markets, with a focus on Europe and North America, where enhanced access to advanced diagnostic solutions can significantly impact hypertension management.

aTENSION. life generates revenue through the sale of its ALDO+ testing services, priced at EUR 183. 20 per test, which can be privately paid by patients or potentially reimbursed through private insurance. The company employs a Prep ‘n’ Ship™ model, allowing laboratories without mass spectrometry capabilities to collect and prepare samples on-site before sending them to specialized labs for analysis.

This model fosters partnerships with clinical laboratories and healthcare providers, enhancing diagnostic capabilities while creating additional income streams for those involved. Transactions typically occur in a B2B structure, where healthcare facilities and laboratories engage directly with aTENSION for their testing needs, contributing to a streamlined and efficient diagnostic workflow within hypertension care. In April 2025, aTENSION. life GmbH raised USD 3 million in Seed funding to support the development of its clinical capabilities.

The company plans to expand its current offerings and introduce new products aimed at further enhancing hypertension diagnostics. Specific new products are currently in the design phase, with targeted geographic expansion into additional European and North American markets planned for the coming years.